Sponsors (2)
The bill expands financial parity and preserves state protections and physician judgment to improve access to oral anticancer drugs, but may introduce utilization barriers, raise plan and taxpayer costs, and leave some coverage decisions uncertain while GAO review proceeds.
Patients prescribed FDA‑approved oral anticancer drugs (including Medicare beneficiaries) will face cost‑sharing parity with IV/injected anticancer drugs, reducing their out‑of‑pocket expenses.
Enrollees are protected from insurer cost‑shifting tactics because plans cannot meet parity requirements by reclassifying benefits or raising out‑of‑pocket costs.
Policymakers (and thus patients) will get an evidence‑based GAO analysis and recommendations that can identify coverage gaps and guide improvements to access and affordability for oral and patient‑administered anticancer drugs.
Patients and providers may face prior authorization and other utilization management for oral anticancer drugs, which can delay access and add administrative burden at critical times.
Employers, employees, and taxpayers could see higher plan drug spending translate into increased premiums or other costs over time if plans cover more expensive oral therapies.
The vague standard of 'clinical appropriateness' could produce inconsistent coverage decisions across plans and providers, creating uncertainty and potential denials for patients.
Based on analysis of 3 sections of legislative text.
Requires group plans that cover provider‑administered anticancer drugs to apply no less favorable cost‑sharing and benefit rules to physician‑prescribed FDA‑approved oral anticancer medications.
Official title: Amend the Employee Retirement Income Security Act of 1974 to require a group health plan (or health insurance coverage offered in connection with such a plan) to provide for cost-sharing for oral anticancer drugs on terms no less favorable than the cost-sharing provided for anticancer medications administered by a health care provider.
Introduced July 15, 2026 by Tina Smith · Last progress July 15, 2026
Requires group health plans and related group insurance that cover provider‑administered anticancer drugs to apply no less favorable cost‑sharing and benefit rules to FDA‑approved, physician‑prescribed oral anticancer medications than they apply to intravenously or injection‑administered anticancer drugs. Plans may retain prior authorization and may not comply by shifting costs or imposing more restrictive limits on oral drugs. The rule applies to plan years beginning on or after January 1, 2027. Directs the Government Accountability Office to study and report to Congress within two years on the law’s effects on out‑of‑pocket costs and access to oral anticancer therapies and to recommend further federal or congressional actions to reduce financial barriers and improve access.